Panzilan (Pantoprazole)

Pantoprazole, the active ingredient in Panzilan, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Panzilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosive lesions and prevents recurrence. - Peptic ulcer disease: supports ulcer healing and reduces risk of re‑bleeding. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

Adverse reactions to pantoprazole may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation. - Dry mouth.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angio‑edema). - Clostridioides difficile‑associated colitis. - Acute interstitial nephritis. - Low magnesium levels (hypomagnesemia) with prolonged use. - Bone fractures with long‑term therapy. - Liver enzyme elevations.

When prescribing pantoprazole, consider the following safety measures: - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for altered absorption of drugs that need an acidic environment. - Monitor long‑term users: watch for signs of hypomagnesemia, bone density loss, and vitamin B12 deficiency. - Pregnancy and lactation: use only if the potential benefit outweighs the risk. - Discontinue cautiously: abrupt cessation may lead to rebound acid hypersecretion. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced absorption due to increased gastric pH. - Atazanavir: markedly decreased plasma concentrations, compromising antiviral efficacy. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Methotrexate: reduced renal clearance may raise serum levels. - Digoxin: slight increase in serum concentration; observe for toxicity signs.